Copied to clipboard!
NCTN_NCORP: A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children (ACCL0431)
Study ID: ACCL0431
NCT Number: NCT00716976
Children's Oncology Group (COG)
Submitted in collaboration with the NCTN/NCORP Data Archive
Trial Title: NCTN_NCORP: A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children (ACCL0431)
Trial Description: RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss.
PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.
Clinical data presented in the following publication(s):
- PMID 27914822
Disease type(s):
- Germ Cell Neoplasm - Germ Cell Neoplasm, Miscellaneous
- Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
- CNS Neoplasm (Primary Tumor) - Embryonal Tumors of the CNS
- CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
- Bone Neoplasm - Osteosarcoma
- Miscellaneous Neoplasm - Solid Tumor, Miscellaneous
Clinical Dataset(s) included:
- NCT00716976-D1 (PMID 27914822): There are three datasets for ACCL0431's primary publication 27914822 (-D1 through -D3). In this dataset there is one row for each patient enrolled. The first 14 variables are used to make Figure 1 (eligibility, random assignment, inclusion in survival and toxicity analyses, treatment received). Patients considered for analysis of study outcomes have the variable analysiset1=1. Variables 15-50 provide patient characteristics (Table 1), outcome (Figures 2 and 3) and hearing loss comparisons (Table 2).
- NCT00716976-D2 (PMID 27914822): There are three datasets for ACCL0431's primary publication 27914822 (-D1 through -D3). This dataset provides the incidence of toxicities. There is one record per patient-cycle. analysiset2=1 for rows included in Table 3 construction. analysiset3=1 for rows included in Table 4 construction.
- NCT00716976-D3 (PMID 27914822): There are three datasets for ACCL0431's primary publication 27914822 (-D1 through -D3). In this dataset, there is one row for each of the 194 serious adverse events detailed on manuscript page 69. These events are reported through the National Cancer Institute, Cancer Therapy Evaluation Program, Adverse Event Reporting System (CTEP-AERS).
You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).
- Type: Interventional
- Archive: The database of Genotypes and Phenotypes (dbGaP)
